menu
    • menu
    [{"orgOrder":0,"company":"Synthonics","sponsor":"RS BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RSBT-001","moa":"Cannabinoid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Synthonics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synthonics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"Synthonics \/ Synthonics"},{"orgOrder":0,"company":"Synthonics","sponsor":"RS BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"RSBT-001","moa":"Cannabinoid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Synthonics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synthonics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"Synthonics \/ Synthonics"},{"orgOrder":0,"company":"Synthonics","sponsor":"RS BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"RSBT-001","moa":"Cannabinoid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Synthonics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synthonics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"Synthonics \/ Synthonics"},{"orgOrder":0,"company":"Synthonics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Chylobinoid","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Synthonics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Synthonics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Synthonics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Synthonics

    Menu

    Synthonics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Synthonics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Synthonics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chylobinoid

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome

                            Details : Chylobinoid is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Restless Legs Syndrome.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 26, 2024

                            Lead Product(s) : Chylobinoid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Synthonics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Synthonics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RSBT-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Recipient : RS BioTherapeutics

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            RS BioTherapeutics Secures $3 Million Seed II Round of Funding

                            Details : RSBT-001 is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 26, 2022

                            Lead Product(s) : RSBT-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Recipient : RS BioTherapeutics

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Synthonics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Synthonics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RSBT-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Recipient : RS BioTherapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RS Biotherapeutics Reports Positive Results From Proof-of-Concept Trial for First Investigational Compound

                            Details : The data from the proof-of-concept trial clearly indicates that RSBT-001, is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid (CBDa) reduces cytokine level, and that this cytokine reduction is appropriately transient.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 11, 2022

                            Lead Product(s) : RSBT-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Recipient : RS BioTherapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Synthonics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Synthonics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RSBT-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Recipient : RS BioTherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound

                            Details : Under the license agreement with Synthonics, Inc. for the exclusive, worldwide right for RS BioTherapeutic's lead compound, RSBT-001, as both an alternative and a complement to corticosteroids for the treatment of chronic obstructive pulmonary disease (C...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 23, 2022

                            Lead Product(s) : RSBT-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Recipient : RS BioTherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth